Publications of interest from Lead Investigators

Professor Jeffrey Braithwaite

Rapport, F. and Braithwaite, J. (2018) Are we on the cusp of a fourth research paradigm? Predicting the future for a new approach to methods-use in medical and health services research. BMC Medical Research Methodology, 18(131). doi: 10.1186/s12874-018-0597-4.

Churruca, K., Ludlow, K., Taylor, N., Long, J.C., Best, S. and Braithwaite, J. (2019) The time has come: embedded implementation research for health care improvement. Journal of Evaluation in Clinical Practice. doi: 10.1111/jep.13100.

Rapport, F., Clay-Williams, R., Churruca, K., Shih, P., Hogden, A. and Braithwaite, J. (2018) The struggle of translating science into action: foundational concepts of implementation science. Journal of Evaluation in Clinical Practice, 24:117–126. doi: 10.1111/jep.12741.

Braithwaite, J., Wears, R.L. and Hollnagel, E. (eds) (2017) Resilient Health Care Volume 3: Reconciling Work-as-Imagined and Work-as-Done. Abingdon, UK, Taylor & Francis. IBSN: 978-1-4987-8056-8

Wears, R.L., Hollnagel, E. and Braithwaite, J. (eds) (2015) Resilient Health Care Volume. 2: The resilience of everyday clinical work, Farnham, Surrey, Ashgate Publishing Ltd. ISBN: 978-1-4724-3782-2

Hollnagel, E., Braithwaite, J., Wears, R.L. (eds) (2013) Resilient Health Care, Farnham, Surrey, Ashgate Publishing Ltd. ISBN: 978-1-4094-6978-0

Braithwaite, J., Marks, D. and Taylor, N. (2014) Harnessing implementation science to improve care quality and patient safety in complex adaptive systems: a literature review and content analysis. International Journal for Quality in Health Care, 26(3): 321-9.

Long, J.C., Cunningham, F.C. and Braithwaite J. (2013) Bridges, brokers and boundary spanners in collaborative networks: a systematic review. BMC Health Services Research, 13: 158.

Runciman, W.B., Hunt, T.D., Hannaford, N.A., Hibbert, P.D., Westbrook, J.I., Coiera, E., Day, R.O., Hindmarsh, D.M., McGlynn, E.A. and Braithwaite, J. (2012) CareTrack: assessing the appropriateness of healthcare delivery in Australia. Medical Journal of Australia, 197(2): 100-105.

Hollnagel, E., Braithwaite, J., Wears, R. (eds) (2013) Resilient Health Care, London, Ashgate.

Greenhalgh, T. … Braithwaite, J … and key international colleagues. (2016) An open letter to The BMJ editors on qualitative research. BMJ, 325: i957.

 

Professor Phil Crowe

Lehane, C., Ho, F., Thompson, S.R., Links, D., Lewis, C., Smee, R., Crowe, P.J. (2016) Neoadjuvant chemoradiation (modified Eilber protocol) versus adjuvant radiotherapy in the treatment of extremity soft tissue sarcoma. Journal of Medical Imaging and Radiation Oncology. 60(4):539-44.

Wang, X., Goldstein, D., Crowe, P., Yang, J. (2013) S3I-201, a novel STAT3 inhibitor, inhibits growth of human soft tissue sarcoma cell lines. World Journal of Cancer Research 08 Jan.

Wang, X., Goldstein, D., Crowe, P., Yang, M., Garrett, K., Zeps, N. and Yang, J.L. (2016) Overcoming resistance of targeted egfr monotherapy by inhibition of stat3 escape pathway in soft tissue sarcoma. Oncotarget 7(16):21496-21509 (14 pages).

Varcoe, R.L., Nammuni, I., Lennox, A.F., Yang, J.L., Crowe, P.J., Walsh, W.R. (2012) Adjunctive Ultrasonography to Minimize Iodinated Contrast Administration During Carotid Artery Stenting: A Randomized Trial. Journal of Endovascular Therapy. 19(5):638-647.

Hwang, S.Y., Warrier, S., Thompson, S., Davidson, T., Yang, J.L. and Crowe, P. (2016) Safety and accuracy of core biopsy in retroperitoneal sarcomas. Asia-Pacific Journal of Clinical Oncology 12(1):e174-e178.

 

Professor David Currow

Hardy, J., Quinn, S., Fazekas, B., Plummer, J., Eckermann, S., Agar, M., Spruyt, O., Rowett, D. and Currow, D. (2012) Randomised, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. Journal of Clinical Oncology 30(29):3611-7.

Currow, D.C., Allingham, S., Yates, P., Johnson, C., Clark, K. and Eagar, K. (2015) Improving national hospice / palliative care service symptom outcomes systematically through point-of care data collection, structured feedback and benchmarking. Support Care Cancer 23(2):307-15.

Johnson, J., Abernethy, A., Davidson, P., Newton, P., Oxberry, S., Bland, M. and Currow, D.C. (2013) The relationship between two performance scales: New York Heart Association class and Karnofsky Performance Scale, AKPS, ECOG. J Pain Symptom Manage 47(3):652-8.

Waller A., Girgis A., Johnson C., Lecathelinais C., Sibbritt D., Forstner D., Liauw W., Currow D.C. (2012) Improving outcomes for people with progressive cancer: Interrupted time series trial of a needs assessment intervention. Journal of Pain and Symptom Management 43(3):569-81.

Currow, D.C., Quinn, S., Agar, M., Fazekas, B., Hardy, J., McCaffrey, N., Eckermann, S., Abernethy, A.P. and Clark, K. (2014) Double-Blind, Placebo-Controlled, Randomized Trial of Octreotide in Malignant Bowel Obstruction, Journal of Pain and Symptom Management doi: 10.1016/j.jpainsymman.2014.09.013.

Ekström, M.P., Bornefalk-Hermansson, A., Abernethy, A.P. and Currow, D.C. (2014) Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. British Medicine Journal 348:g445.

 

Professor Geoff Delaney

Barton, M.B., Jacob, S., … Delaney, G.P. (2014) Estimating the demand for radiotherapy from the evidence: a review of changes from 2003 to 2012. Radiotherapy + Oncology 112(1):140-144.

Delaney, G.P. and Barton, M.B. (2015) Evidence-based decision trees and their use in estimating optimal radiotherapy utilization rates. Clinical Oncology 27(2):70-76.

Delaney, G.P., Ghandidasan, S., Terlich, F., Walton, R., Baker, D. and Currow, D. (2016) The Pattern of Use of Hypofractionated Radiation Therapy for Early Stage Breast Cancer in New South Wales, Australia 2008-2012. Int J Radiat Oncol Biol Phys., 96(2):266-272.

Fong A., Shafiq J., … Delaney G.P. (2012). A comparison of systemic breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of “optimal” therapy. The Breast 21(4):562-569.

Fong, A., Shafiq, J., … Delaney, G.P. (2012). A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee) and Australia (Western Australia) with models of “optimal” therapy. The Breast 21(4):570-577.

 

Professor Jonathan Karnon

Briggs, A.H., …. Karnon et al. (2012) Model parameter estimation and uncertainty analysis. Value in Health. 32(5):722-732.

Crane, …, Karnon. (2013) Accounting for costs, QALYs, and capacity constraints. Medical Decision Making. 33(8):986-997.

Partington, …, Karnon. (2016) Screening for important unwarranted variation in clinical practice: a triple-test of processes of care, costs and patient outcomes. Australian Health Review. Mar 3 [Epub ahead of print].

Karnon et al. (2012) Modeling using discrete event simulation. Value in Health. 15:821– 827.

Karnon et al. (2013) A risk adjusted cost-effectiveness analysis of alternative models of nurse involvement in obesity management in primary care. Obesity. 21(3):472-9.

 

Professor Richard Kefford AM

Wilmott, J.S., Long, G.V., Howle, J.R., Haydu, L.E., Sharma, R.N., Thompson, J.F., Kefford, R.F., Hersey, P. and Scolyer, R.A. (2012) Clinical Cancer Research. 18:1386-94.

Falchook, G.S., Long, G.V., Kurzrock, R., Kim, K.B., Arkenau, T.H., Brown, M.P., Hamid, O., Infante, J.R., Millward, M., Pavlick, A.C., O’Day, S.J., Blackman, S.C., Curtis, C.M., Lebowitz, P., Ma, B., Ouellet, D. and Kefford, R.F. (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. The Lancet. 379:1893-901.

Flaherty, K.T., Infante, J.R., Daud, A., Gonzalez, R., Kefford, R.F. et al (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New England Journal of Medicine. 367:1694-703.

Rizos, H., Menzies, A.M., Pupo, G.M., Carlino, M.S., Fung, C., Hyman, J., Haydu, L.E., Mijatov, B., Becker, T.M., Boyd, S.C., Howle, J., Saw, R., Thompson, J.F., Kefford, R.F., Scolyer, R.A. and Long, G.V. (2014) BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical Cancer Research. 20(7):1965-77.

Robert, C., Ribas, A., Wolchok, J.D., Hodi, F.S., Hamid, O., Kefford, R., Weber, J.S., Joshua, A.M., Hwu, W.J., Gangadhar, T.C., Patnaik, A., Dronca, R., Zarour, H., Joseph, R.W., Boasberg, P., Chmielowski, B., Mateus, C., Postow, M.A., Gergich, K., Elassaiss- Schaap, J., Li, X.N., Iannone, R., Ebbinghaus, S.W., Kang, S.P. and Daud A. (2014). Antiprogrammed- death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. The Lancet. 384(9948):1109-17.

 

Associate Professor Winston Liauw

Chua, T.C., Moran, B.J., Sugarbaker, P.H., Levine, E.A., Glehen, O., Gilly, F.N., Baratti, D., Deraco, M., Elias, D., Sardi, A., Liauw, W., Tan, T.D., Barrios, P., Gomez Portilla, A., de Hingh, I.H., Ceelen, W.P., Pelz, J.O., Piso, P., Gonzalez-Moreno, S., Van Der Speeten, K., Morris, D.L. (2012) Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Journal of Clinical Oncology, 30(20):2449-56.

Johnson K.R., Liauw W., Lassere M.N.D. (2015) Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: A systematic review. Annals of Oncology 26(3):485-96.

Chua T.C., Liauw W., Chu F., Morris D.L. (2012) Viewing metastatic colorectal cancer as a curable chronic disease. American Journal of Clinical Oncology. 35(1):77-80.

Siu L.L., Shapiro J.D., Jonker D.J., Karapetis C.S., Zalcberg J.R., Simes J., Couture F., Moore M.J., Price T.J., Siddiqui J., Nott L.M., Charpentier D., Liauw W., Sawyer M.B., Jefford M., Magoski N.M., Haydon A., Walters I., Ringash J., Tu D., O’Callaghan C.J. (2013) Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wildtype K-RAS colorectal carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 trial. Journal of Clinical Oncology, 31(19):2477-84.

 

Professor Ian Olver AM

Olver, I. (2015) Role of Rolapitant in chemotherapy-induced emesis. Lancet Oncology, Aug 10 [Epub before print]. Doi: 10.1016/S1470-2045(15)00096-0.

Olver, I. et al. (2016) Updated MASCC/ESMO consensus recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. Support Care Cancer. Aug 30 [Epub ahead of print]. Doi:10.1007/s00520-016-3391-z.

Olver, I., von Dincklage, J., Nicholson, J. and Shaw, T. (2016) Improving uptake of wikibased guidelines with Qstream education. Medical Education, 50(5):590-591.

Fennell, K.M. … Olver, I. (2016) The consumer-driven development and acceptability testing of a website designed to connect rural cancer patients and their families, carers and health professionals with appropriate information and psychosocial support. European Journal of Cancer Care. Jul 13 [Epub before print]. Doi:10.1111/ecc.12533.

Smith, A.B., King, M., Butow, P., Luckett, T., Grimison, P., Toner, G.C., Stockler, M., Hovey, E., Stubbs, J., Hruby, G., Gurney, H., Turner, S., Alam, M., Cox, K. and Olver, I. (2013) The prevalence and correlates of supportive care needs in testicular cancer survivors: a crosssectional study. Psychooncology. 22(11): 2557-2564. doi: 10.1002/pon.3323.

 

Professor Robyn Ward AM

Ward, R.L. … Haas, M. (2015) Cost of cancer care for patients undergoing chemotherapy: The Elements of Cancer Care study. Asia-Pacific Journal of Clinical Oncology. 11(2):178-86.

Ward, R.L., Dobbins, T., Lindor, N.M., Rapkins, R.W. and Hitchins, M.P. (2013) Identification of constitutional MLH1 epimutations and promoter variants in colorectal cancer patients from the colon cancer family registry. Genetics in Medicine, 15(1):25-35.

Sloane, M.A. … Ward, R.L. (2015) Mosaic Epigenetic inheritance as a cause of early-onset colorectal cancer. JAMA Oncology, 1(7): 953-957.

Ward, R.L., Hicks, S. and Hawkins, N.J. (2013) Population-based molecular screening for Lynch syndrome: implications for personalized medicine. Journal of Clinical Oncology, 31(20):2554-2562.

Hesson, L.B. … Ward, R.L. (2016) Integrated Genetic, Epigenetic and Transcriptional Profiling Identifies Molecular Pathways in the Development of Laterally Spreading Tumours. Mol Cancer Res. Sep 26. pii: molcanres.0175.2016. [Epub ahead of print].

 

Professor Johanna Westbrook

Westbrook, J.I. et al. (2012) Effects of two commercial electronic prescribing systems on prescribing error rates in hospital in-patients: a before and after study. PLoS Medicine. 9(1):e1001164.

Westbrook, J.I. et al. (2013) Impact of an electronic medication management system on hospital doctors’ and nurses’ work: A controlled pre post, time and motion study. Journal of the American Medical Informatics Association, 20(6):1150-1158.

Westbrook, J.I. et al. (2013) The safety of electronic prescribing: Rates, manifestations and mechanisms of system-related errors associated with two commercial systems in hospitals. Journal of the American Medical Informatics Association. 20(6):1159-1167.

Westbrook, J.I. et al. (2015) What are incident reports telling us? A comparative study at two Australian hospitals of medication errors identified at audit, detected by staff and reported to an incident system. International Journal of Quality in Health Care, 27(1):1-9.

Sinskey, C. … Westbrook, J., Tutty, M., Blike, G., (2016) Allocation of physician time in ambulatory practice: A time and motion study in 4 specialties. Annals of Internal Medicine, DOI:10.7326/M16-0961.